Bovine mesenteric venous graft as an alternative conduit in patients with cyanotic heart disease with e-polytetrafluoroethylene graft failure caused by thrombophilic factor positivity after modified Blalock-Taussig shunt

• Published in: The Heart surgery forum Vol. 11; no. 1; p. E37
• Main Authors: Akbulut, B, Dogan, Omer Faruk, Guvener, M, Yilmaz, M, Yorgancioglu, C, Karagoz, T, Ozkutlu, S, Demircin, M, Dogan, R
• Format: Journal Article
• Language: English
• Published: United States 2008
• Subjects: Animals; Arteriovenous Shunt, Surgical; Blood Coagulation Factors; Cattle; Cyanosis - surgery; Female; Graft Survival; Heart Defects, Congenital - surgery; Humans; Male; Mesenteric Veins - transplantation; Polytetrafluoroethylene; Prospective Studies; Risk Factors; Thrombophilia - etiology; Transplantation, Heterologous; Transplants; Treatment Failure; Vascular Patency
• ISSN: 1522-6662
• DOI: 10.1532/HSF98.20071064

Modified Blalock-Taussig shunt (MBTS) is a palliative operation for cyanotic congenital heart disease (CCHD) in patients for whom total correction is not appropriate. Many synthetic or biologic grafts have been proposed as alternative shunt materials. The use of a bovine mesenteric venous graft (BMVG) as a systemic-to-pulmonary artery shunt conduit without the administration of antiaggregant and anticoagulant has been proposed as a treatment for neonates with CCHD, but few reports address the importance of thrombophilic risk factors in MBTS and bovine venous graft as a shunt material. We used BMVG as a shunt material without any antiaggregant or antiplatelet regimen in 13 patients with CCHD, all of whom were candidates for MBTS and had thrombophilic risk factors assessed in our initial study. Early shunt failure occurred in the first 3 patients and was attributed to less surgical experience with this graft. No complications were attributable to graft material or surgery itself. In all cases functioning MBTSs were observed on follow-up. Our study results show that thrombophilic factors should be evaluated before the MBTS procedure. BMVG could be the choice of graft for use without the administration of antiaggregant and anticoagulants in patients with thrombophilic risk factors.